GENB

Generate Biomedicines Inc

13.21

Nov 02 • 3:59 PM ET -1.25 (-8.64%)

13.00

Aftermarket • 5:00 PM ET -0.21 (-1.59%)

Healthcare Biotechnology USA Small NASD

Oct 28, 2:02 PMAnthropic Claude CAR-T redesign with Generate lifts GENB 16% in session

Peers: ABSI RXRX UPB ABCL AMGN REGN XNCR ZYME SDGR AZN

| Held by: VTI ARKG IWM VXF JTEK IWO SBIO VTWO SCHA IWN

Scroll to Statements

Index	RUT
Market Cap	1.70B
Enterprise Value	1.30B
Income	-
Sales	-
Book/sh	3.56
Cash/sh	3.56
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	312
IPO	Feb 27, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.72
P/C	3.71
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.30
Current Ratio	8.30
Debt/Eq	0.14
LT Debt/Eq	0.11
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-2.29
EPS next Q	-0.56
EPS this Y	49.87%
EPS next Y	-0.73%
EPS next 5Y	26.80%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-2.30% 19.13%

Insider Own	56.98%
Insider Trans	0.00%
Inst Own	26.62%
Inst Trans	8.52%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.28%
SMA50	-11.57%
SMA200	-6.08%
Trades

Shs Outstand	128.27M
Shs Float	55.21M
Short Float	16.18%
Short Ratio	7.65
Short Interest	8.93M
52W High	22.67 -41.73%
52W Low	11.00 20.09%
Volatility	8.46% 6.95%
ATR (14)	1.05
RSI (14)	45.87
Beta	-
Rel Volume	0.64
Avg Volume	1.17M
Volume	744,555

Perf Week	6.96%
Perf Month	-3.51%
Perf Quarter	-7.49%
Perf Half Y	-8.64%
Perf YTD	-11.93%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	27.00
Prev Close	14.46
Price	13.21
Change %	-8.64%

Consensus

Strong Buy

Avg. Price Target

$27.00

Implied Upside

+104.4%

Analysts6incl. previous ratings

Rating Distribution6 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 13, 2026	Initiated	HH.C. Wainwright	Buy	$16	+21.1%
Mar 24, 2026	Initiated	PPiper Sandler	Overweight	$24	+81.7%
Mar 24, 2026	Initiated	MMorgan Stanley	Overweight	$20	+51.4%
Mar 24, 2026	Initiated	GGuggenheim	Buy	$30	+127.1%
Mar 24, 2026	Initiated	GGoldman	Buy	$26	+96.8%
Mar 24, 2026	Initiated	CCantor Fitzgerald	Overweight

Oct-29-26 10:43AM	Anthropic Announced New Achievements in Drug Research and Lab Work. An Expert Says AI is 'Changing the Medical Field.' (International Business Times)
Oct-22-26 07:00AM	Generate Biomedicines to Participate in November Investor Conferences (GlobeNewswire)
Oct-14-26 12:17PM	Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate (Pharmaceutical Technology)
Oct-13-26 04:30PM	Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases (GlobeNewswire) -11.45%
Oct-01-26 07:00AM	Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of 'Armored' CAR T Therapy for Ovarian Cancer (GlobeNewswire) -8.12%
07:09AM	Loading…
Sep-08-26 07:09AM	Generate Biomedicines Inc. to Participate in September Investor Conferences (GlobeNewswire)
Aug-28-26 07:59AM	Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines (BioPharma Dive)
Aug-27-26 03:18PM	Cathie Wood Sends a $20 Million Signal on Broadcom Stock (GuruFocus.com)
Aug-25-26 11:10AM	Generate Biomedicines stock jumps as post-IPO lock-up set to expire (Proactive) +15.01%
Aug-17-26 12:12PM	Two Positions Make Up 80% of Nvidia's $63.4 Billion Portfolio (GuruFocus.com)
Aug-06-26 07:00AM	Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
06:21AM	Generate Biomedicines: Q2 Earnings Snapshot (Associated Press)
Jul-10-26 08:57AM	Cathie Wood Dumps AMD, Doubles Down on Meta Stock (GuruFocus.com) -8.87%
Jul-01-26 09:04AM	Cathie Wood Doubles Down on AI, Loads Up on Tesla, Palantir, and SpaceX (GuruFocus.com)
Jun-22-26 08:00AM	AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts (PR Newswire) +9.66%
04:20PM	Loading…
May-28-26 04:20PM	Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference (PR Newswire)
May-07-26 06:24AM	Generate Biomedicines: Q1 Earnings Snapshot (Associated Press) -11.21%
06:16AM	Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update (PR Newswire)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARNOLD FRANCES	Director	Oct 29 '26	Proposed Sale	16.19	11,409	184,733		Oct 29 04:12 PM
ARNOLD FRANCES	Director	Sep 02 '26	Proposed Sale	16.16	32,210	520,631		Sep 02 04:20 PM
ARNOLD FRANCES	Director	Sep 01 '26	Proposed Sale	16.00	1,000	16,002		Sep 01 04:27 PM
Nally Michael	Chief Executive Officer	Mar 04 '26	Buy	12.00	20,000	240,000	572,707	Mar 06 04:55 PM
Grous Beth	Chief People Officer	Mar 02 '26	Buy	16.00	300	4,800	300	Mar 02 06:05 PM
Silvers Jason	President & CFO	Mar 02 '26	Buy	16.00	2,000	32,000	1,000	Mar 02 05:54 PM
AFEYAN NOUBAR	Director	Mar 02 '26	Buy	16.00	4,687,500	75,000,000	15,264,724	Mar 02 05:52 PM
Mendillo Jane L	Director	Mar 02 '26	Buy	16.00	1,500	24,000	1,500	Mar 02 05:47 PM
AFEYAN NOUBAR	Director	Mar 02 '26	Buy	16.00	4,687,500	75,000,000	15,264,724	Mar 02 05:42 PM

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company was founded in 2018, and is headquartered in Somerville, MA.

Co-founder & Independent Chair of the BoardDr. Noubar B. Afeyan Ph.D.

CEO & DirectorMr. Michael T. Nally M.B.A.

M.D.Dr. Jason E. Silvers J.D.

Co-Founder & CTODr. Gevorg Grigoryan Ph.D.

Co-FounderMs. Molly Gibson Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GENB

Generate Biomedicines Inc

Upgrade your Finviz experience